Panthera Dental announced Panthera DUO, an ordering option that provides two appliances of the same design ordered together for the same patient. With choice of two different designs- Panthera Classic or Panthera X3– Panthera DUO helps dental practices maintain continuity of care and support adherence for patients who cannot afford […]
Clinical Insights
Dental Sleep Medicine | Sleep Disorders | Testing Modalities & Diagnostics | Patient Health | Pharmaceuticals | Research/Studies
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
Inspire Medical Systems, Inc. published Inspire V clinical outcomes data from its Singapore clinical study, as well as the Company’s limited market release in the United States, including single-site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical […]
SleepSpace Wins NIH Grant to Turn Phones Into Sleep Therapy Tools
SleepSpace (Proactive Life, Inc.), an AI-powered sleep technology company founded by NIH-funded sleep scientist Dr. Daniel Gartenberg, PhD, announced today it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). The award supports development […]
Nylon flexTAP Becomes the First FDA-cleared 3D-Printed Midline Oral Appliance for Sleep Apnea
Airway Management proudly announces a historic milestone with the FDA clearance of Nylon flexTAP®, the world’s first digitally printed single-point midline oral appliance device for sleep apnea. This revolutionary device redefines patient care by combining cutting-edge patented Vertex Technology® with unparalleled comfort and efficacy, now FDA cleared for mild to moderate obstructive […]
Expert Insights: Dormotech Talks with Yale’s Dr. Meir Kryger on the Changing Landscape of Sleep Testing
Dormotech shares the release of a compelling expert highlight interview featuring Dr. Meir Kryger, Emeritus Professor at Yale School of Medicine. In this exclusive discussion, Dr. Kryger, a revered figure in the sleep industry who has been involved in sleep medicine since 1974, shares his unique perspective on the transformative […]
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Eisai Co., Ltd. announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. These data demonstrate that once-daily dosing of […]
Patient Primer – Oral Appliance Therapy for Sleep Apnea
If your dentist or sleep physician has recommended oral appliance therapy to treat your obstructive sleep apnea (OSA), you might be wondering how it works. This guide walks you through the basics so you’ll know what to expect and how to get the best results. What Is a Mandibular Advancement […]
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore. Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]
The Power of WUN
Attendees traveled from near and far to join us in person and online for the 2025 Wake Up Narcolepsy National Summit in Raleigh-Durham, N.C. Hosted in a different city each year, the summit provides a place where industry professionals, clinicians, individuals with narcolepsy, and family members can come together and […]
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. (“XWPharma”) together announced today that Avadel has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a GABAB receptor agonist, for all indications, including the treatment of sleep disorders, such […]













